WASHINGTON, July 14 -- Food and Drug Administration has issued a notice called: Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability.
The notice was published in the Federal Register on July 14 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.
Summary: The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Psychedelic Drugs: Considerations for Clinical Investigations." Because interest in the therapeutic potential of psychedelic drugs has been increasing and designing clinical trials to evaluate these compounds presents unique challenges, FDA developed the draft guidance to present found...